By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Full Year 2020 Financial and Operational Results On March 11, 2021 Lipocine (NASDAQ:LPCN) filed its 2020 Form 10-K and posted its earnings release for the twelve month period ending December 31, 2020. The company reported zero revenues and a net loss per share of ($0.38) compared to 2019 revenues of $0.2 million and loss of ($0.50) per share. After a multi-year effort and several submissions, Tlando was finally approved by the FDA on December 8, 2020. The approval was tentative and requires the expiry of marketing exclusivity for competing oral testosterone product Jatenzo or successful legal action by Lipocine prior to Tlando being cleared for marketing. Lipocine is now considering its options on how to proceed with commercialization of Tlando. Other important accomplishments include results from the LiFT study for NASH which demonstrated LPCN 1144’s ability to reduce liver fat and improve liver injury markers.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate update.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference and the Lytham Partners Spring 2021 Investor Conference. Both conferences will be held virtually. Presentation details are below.